Logo
x

Search category

Subscribe Now

COVID-19 Vaccine

Novavax’s Nuvaxovid COVID-19 Vaccine Receives the CHMP Recommendation for Expanded Conditional Marketing Authorization

Novavax’s Nuvaxovid COVID-19 Vaccine Receives the CHMP Recommendation for Expanded Conditional Marketing Authorization

Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19

Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19

Novavax Receives the US FDA Emergency Use Authorization for NVX-CoV2373 in Adolescents Aged 12 Through 17 Years

Novavax Receives the US FDA Emergency Use Authorization for NVX-CoV2373 in Adolescents Aged 12 Through 17 Years

Sanofi and GSK Report Results of COVID-19 Vaccine in the P-III (VAT08) Trial Against Omicron

Sanofi and GSK Report Results of COVID-19 Vaccine in the P-III (VAT08) Trial Against Omicron

Pfizer-BioNTech’s COVID-19 Vaccine Receive the US FDA’s EUA for COVID-19 in Children Aged 6 Months through 4 Years of Age

Pfizer-BioNTech’s COVID-19 Vaccine Receive the US FDA’s EUA for COVID-19 in Children Aged 6 Months through 4 Years of Age

Pfizer and BioNTech Seek the US FDA’s EUA for Booster Dose of their COVID-19 Vaccine in Children Aged 5 Through 11 Years

Pfizer and BioNTech Seek the US FDA’s EUA for Booster Dose of their COVID-19 Vaccine in Children Aged 5 Through 11 Years

Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2022 PharmaShots - All Rights Reserved.